Royal Bank of Canada
IMNP

Royal Bank of Canada’s Immune Pharmaceuticals Inc. IMNP Stock Holding History

Royal Bank of Canada’s Portfolio IMNP Stock Details IMNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-1
Closed – – 6995
2018
Q1 		$0 Hold
1
– – ﹤0.01% 7158
2017
Q4 		$0 Hold
1
– – ﹤0.01% 7229
2017
Q3 		$0 Buy
+1
New +$2 ﹤0.01% 7214

Other funds holding IMNP

CH
CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EDRH
Edmond de Rothschild Holding Chambesy, Switzerland $6.91B AUM 19.7% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
IP
Intellectus Partners San Francisco, California $490M AUM 35.11% 1-Year Est. Return
FDCDDQ
Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $27.8B AUM 31.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Royal Bank of Canada's IMNP Position: Q2 2018 in Review

Royal Bank of Canada sold out of Immune Pharmaceuticals Inc. (IMNP) in Q2 2018, closing a stake of 1 share.

Royal Bank of Canada first reported a position in IMNP in Q3 2017 and held it in 3 quarters. The position peaked at $0 in Q1 2018. 13 funds tracked by Wall St. Rank hold IMNP as of Q2 2018.

  • Royal Bank of Canada reported no remaining Immune Pharmaceuticals Inc. position as of Q2 2018 after selling out during the quarter.
  • Royal Bank of Canada sold 1 Immune Pharmaceuticals Inc. share in Q2 2018.
  • Royal Bank of Canada first reported a position in Immune Pharmaceuticals Inc. in Q3 2017 and held it in 3 quarters.
  • Royal Bank of Canada's Immune Pharmaceuticals Inc. position peaked at $0 in Q1 2018.
  • 13 funds tracked by Wall St. Rank held Immune Pharmaceuticals Inc. as of Q2 2018.

Based on Royal Bank of Canada's 13F filing for Q2 2018, filed 14 Aug 2018.